Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel as Radiosensitizer in Head and Neck Cancer
NCT06360978Phase 2Not yet recruiting
- Sponsor
- Assiut University
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Assiut University. Primary endpoint: Progression Free Survival at 2 years. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
docetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06360978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360978.